Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon J Freeman

Showing results (231-240 of 348) with videos related to

Pageof 35
Sort By:
Nature|May 3, 2023
Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistanceJoon Seok Park, Francesca S Gazzaniga, Meng Wu, et al.
Cell|June 26, 2018
LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint BlockadeWanqiang Sheng, Martin W LaFleur, Thao H Nguyen, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 4, 2019
Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockadeMohammad Rashidian, Martin W LaFleur, Vincent L Verschoor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2019
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUNAbdallah Flaifel, Wanling Xie, David A Braun, et al.
Nature|August 9, 2016
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapySe Jin Im, Masao Hashimoto, Michael Y Gerner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2018
Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma TherapyCarmela Passaro, Quazim Alayo, Isabella De Laura, et al.
Immunity|February 24, 2017
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine LeiomyosarcomaSuzanne George, Diana Miao, George D Demetri, et al.
Cancer Immunology Research|June 7, 2014
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockadeZachary A Cooper, Vikram R Juneja, Peter T Sage, et al.
Science Advances|December 8, 2022
Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivoJames A Torchia, Alexander H Tavares, Laura S Carstensen, et al.
The Journal of General Virology|January 29, 2015
Nef promotes evasion of human immunodeficiency virus type 1-infected cells from the CTLA-4-mediated inhibition of T-cell activationMohamed El-Far, Petronela Ancuta, Jean-Pierre Routy, et al.
Pageof 35

Showing results (231-240 of 348) with videos related to

Sort By:
Pageof 35
Nature|May 3, 2023
Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistanceJoon Seok Park, Francesca S Gazzaniga, Meng Wu, et al.
Cell|June 26, 2018
LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint BlockadeWanqiang Sheng, Martin W LaFleur, Thao H Nguyen, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 4, 2019
Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockadeMohammad Rashidian, Martin W LaFleur, Vincent L Verschoor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2019
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUNAbdallah Flaifel, Wanling Xie, David A Braun, et al.
Nature|August 9, 2016
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapySe Jin Im, Masao Hashimoto, Michael Y Gerner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2018
Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma TherapyCarmela Passaro, Quazim Alayo, Isabella De Laura, et al.
Immunity|February 24, 2017
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine LeiomyosarcomaSuzanne George, Diana Miao, George D Demetri, et al.
Cancer Immunology Research|June 7, 2014
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockadeZachary A Cooper, Vikram R Juneja, Peter T Sage, et al.
Science Advances|December 8, 2022
Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivoJames A Torchia, Alexander H Tavares, Laura S Carstensen, et al.
The Journal of General Virology|January 29, 2015
Nef promotes evasion of human immunodeficiency virus type 1-infected cells from the CTLA-4-mediated inhibition of T-cell activationMohamed El-Far, Petronela Ancuta, Jean-Pierre Routy, et al.
Pageof 35